Effects of Strontium-Hydroxyapatite Mediated Active Compounds from Hippocampus Kuda Bleeler (HKB) on Osteogenesis

Chengyong Li,Lei He,Zhong-Ji Qian,Pengzhi Hong,Qiong Yuan,Chunxia Zhou

doi:10.3390/coatings9020141

Abstract

Porous hydroxyapatite as a drug carrier is very popular and has many clinical applications. However, traditional hydroxyapatite materials have limited osteogenic capacity. Therefore, the development of a new hydroxyapatite drug delivery system is essential for bone tissue engineering. In this study, the metal element Sr was used to replace Ca, and the SrHA microspheres were successfully prepared by hydrothermal reaction. Scanning electron microscopy (SEM), X-ray diffraction (XRD), and X-ray photoelectron spectroscopy (XPS) were used to characterize SrHA (strontium-doped hydroxyapatite) microspheres obtained from hydrothermal reaction conditions. In addition, the drug utility was enhanced by loading the marine active compound 1-(5-bromo-2-hydroxy-4-methoxyphenyl)-ethanone (HKB). Furthermore, after co-culture with preosteoblasts, experiments indicated that HKB/SrHA composite microspheres had a more significant effect on the proliferation and differentiation of cells compared to pure SrHA. These HKB/SrHA composite microspheres may be applied to the drug delivery system of bone tissue repair.

Highlights

In recent years, osteoporosis, bone defects, and osteomyelitis have become one of the chronic diseases that plague the health of middle-aged and elderly people in various countries
Due to some external factors such as age, heredity, and lifestyle, the balance between bone resorption and formation is disrupted, resulting in osteoporosis due to the loss of bone mass. Basic supplements such as calcium [3], vitamin D [4,5] and related derivatives, bone loss inhibitors and bone formation promoters play an important role in the treatment of osteoporosis [6]
Osteon loss inhibitors such as estrogen can reduce the production of osteoclasts [7], and bisphosphonates inhibit osteoclast activity [8], thereby inhibiting bone resorption and preventing bone loss

Summary

Introduction

Osteoporosis, bone defects, and osteomyelitis have become one of the chronic diseases that plague the health of middle-aged and elderly people in various countries. Due to some external factors such as age, heredity, and lifestyle, the balance between bone resorption and formation is disrupted, resulting in osteoporosis due to the loss of bone mass Basic supplements such as calcium [3], vitamin D [4,5] and related derivatives, bone loss inhibitors and bone formation promoters play an important role in the treatment of osteoporosis [6]. Osteon loss inhibitors such as estrogen can reduce the production of osteoclasts [7], and bisphosphonates inhibit osteoclast activity [8], thereby inhibiting bone resorption and preventing bone loss. Polygonatum polysaccharide can promote osteogenic differentiation of mouse bone marrow mesenchymal stem cells through the Coatings 2019, 9, 141; doi:10.3390/coatings9020141 www.mdpi.com/journal/coatings

Methods

Results

Conclusion